Greener Peptides, Oligonucleotides, and ADCs
Symposium Organizer: Subha Mukherjee, Bristol-Myers Squibb
Peptides, Oligonucleotides, and antibody-drug conjugates (ADCs) are an area of significant growth within the biopharma industry. However, the current state of the art in peptide and oligonucleotide syntheses utilize primarily legacy technologies, with little focus on green chemistry and engineering. Waste generated from current peptide and oligonucleotide processes ranges from 3,000-15,000 kg/kg API (10-50 mer products) with multiple usages of highly hazardous reagents and solvents. Contributing to the poor environmental profile is the pervasive and extensive use of chromatography to produce peptide and oligonucleotide products with required quality attributes. This session will explore how improved synthetic methodologies, safer coupling reagents, solvent selection, and the minimization of chromatography play a vital role in improving the green chemistry profile for peptide and oligonucleotide processes. This session will also explore greener approaches to ADCs, which are complex macromolecular therapeutic agents. In ADCs, antibodies are tethered to cytotoxic payloads via linker molecules to provide dual benefit of excellent target specificity of antibodies and high potency of small molecule payloads. However, this complex architecture presents profound green chemistry challenges. This session will explore the complexity of linker-drug process chemistry.